Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 11/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tymazoline SCHEMBL29387735 | 1.00 | NISCH (0.70) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| Tymazoline SCHEMBL4415590 | 0.99 | NISCH (0.68) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| Tymazoline SCHEMBL28142132 | 0.94 | NISCH (0.81) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL7982763 | 0.87 | NISCH (0.56) | NISCHADRA1AADRA1BADRA1DADRA2A | |
| Fenoxazoline SCHEMBL193061 | 0.82 | NISCH (1.00) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| Fenoxazoline SCHEMBL317133 | 0.81 | NISCH (0.97) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| Fenoxazoline SCHEMBL1650113 | 0.81 | NISCH (0.97) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL11265817 | 0.81 | NISCH (0.58) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL10777341 | 0.80 | NISCH (0.60) | NISCHADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL11256297 | 0.79 | ADRA1A (0.58) | NISCHADRA1AADRA1BADRA1DHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 716 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-1744683-B1 | APPARATUS AND METHOD FOR TRANSDERMAL DELIVERY OF PARATHYROID HORMONE AGENTS | ALZA CORP (US) | 2016-03-16 | — | — | EP | claimed |
| EP-2731606-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | Allergan, Inc. (US) | 2014-05-21 | — | — | EP | claimed |
| CN-103796652-A | Gel compositions of oxymetazoline and methods of use | ALLERGAN INC | 2014-05-14 | — | — | CN | claimed |
| CN-103221070-A | Shear controlled release for stenotic lesions and thrombolytic therapies | HARVARD COLLEGE | 2013-07-24 | — | — | CN | claimed |
| EP-2611466-A2 | SHEAR CONTROLLED RELEASE FOR STENOTIC LESIONS AND THROMBOLYTIC THERAPIES | President and Fellows of Harvard College (US) | 2013-07-10 | — | — | EP | claimed |
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-03-28 | — | — | US | claimed |
| WO-2013028909-A1 | COMBINATION THERAPY FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | WO | claimed |
| US-8361022-B2 | Apparatus for transdermal delivery of parathyroid hormone agents | ALZA CORPORATION (US) | 2013-01-29 | — | — | US | claimed |
| WO-2013010032-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | ALLERGAN, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-1999015203-A1 | USE OF COMBINATIONS COMPRISING NON-SEDATING ANTIHISTAMINES AND ALPHA-ADRENERGIC DRUGS FOR THE TOPICAL TREATMENT OF RHINITIS/CONJUNCTIVITIS AND COLD, COLD-LIKE AND/OR FLU SYMPTOMS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-01 | — | — | WO | claimed |
| EP-0903151-A1 | Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms | ASTA Medica Aktiengesellschaft (DE) | 1999-03-24 | — | — | EP | claimed |
| EP-0550921-B1 | Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug | ZAMBON SPA (IT) | 1999-03-17 | — | — | EP | claimed |
| US-5334138-A | Drug delivery; mixture of active material and vasoconstrictor | NORTH CAROLINA STATE UNIVERSITY (US) | 1994-08-02 | — | — | US | claimed |
| EP-0448299-B1 | Composition for increased skin concentration of active agents by iontophoresis | BECTON DICKINSON CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0550921-A1 | Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug | ZAMBON GROUP S.p.A. (IT) | 1993-07-14 | — | — | EP | claimed |
| EP-0448299-A2 | Composition for increased skin concentration of active agents by iontophoresis | Becton, Dickinson and Company (US) | 1991-09-25 | — | — | EP | claimed |
| EP-0086428-B1 | ANTIDIARRHOEA VETERINARY COMPOSITION, ITS PRODUCTION AND ORAL DOSER CONTAINING IT | BEECHAM GROUP PLC (GB) | 1987-07-29 | — | — | EP | claimed |
| EP-0025269-B1 | ANTI-DIARRHOEA VETERINARY COMPOSITION | BEECHAM GROUP PLC (GB) | 1985-11-13 | — | — | EP | claimed |
| EP-0086428-A1 | Antidiarrhoea veterinary composition, its production and oral doser containing it | BEECHAM GROUP PLC (GB) | 1983-08-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079379-A1 | GEL COMPOSITIONS OF OXYMETAZOLINE AND METHODS OF USE | CUTA, PDE3A, PTGIS | NISCH 586/4885ADRA1A 138/4885ADRA1B 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.